» Articles » PMID: 21676374

Quality of Life in a German Graves Orbitopathy Population

Overview
Journal Am J Ophthalmol
Specialty Ophthalmology
Date 2011 Jun 17
PMID 21676374
Citations 44
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To evaluate the validity and responsiveness of a German-language version of the disease-specific Graves orbitopathy quality-of-life questionnaire (GO-QOL).

Design: Prospective cross-sectional study.

Methods: At a multidisciplinary university orbital center, 310 consecutive unselected Graves orbitopathy outpatients answered the GO-QOL before undergoing complete ophthalmic and endocrine assessment. The main outcome measures were the GO-QOL and its 2 subscales, Visual Functioning and Appearance.

Results: The QOL scores for the subscales Visual Functioning and Appearance were (mean ± SE) 72.5 ± 1.4 and 71.3 ± 1.5, respectively. Visual Functioning and Appearance were higher in mild (82.2 ± 2.2 and 86.0 ± 17.6) than in moderate to severe (66.6 ± 1.8, p < .001, 95% CI 15.6-2.9 and 65.5 ± 25.5, P < .001, 95% CI 15.1-26.0) and in sight-threatening Graves orbitopathy (41.9 ± 9.9, P < .001, 95% CI 25.4-55.3 and 58.5 ± 9.0, P < .001, 95% CI 15.0-39.4). Visual Functioning and Appearance were also lower in active (63.3 ± 2.2 and 64.5 ± 2.2) than in inactive stages (77.0 ± 1.9; P < .001, 95% CI 7.9-19.3 and 78.3 ± 1.8, P < .001, 95% CI 8.2-19.2). Visual Functioning was 81.6 ± 1.8 in patients without and 62.4 ± 2.0 in patients with diplopia (P < .001, 95% CI 13.8-24.6). Appearance was lower in those receiving psychotherapy (64.7 ± 3.2) than in those without psychotherapy (74.6 ± 1.6, P = .005, 95% CI 3.0-16.7). Significant ceiling effects (≥15% at the highest value of the subscale) were observed for Appearance in 59 patients (19%) and for Visual Functioning in 85 patients (27%).

Conclusion: The German-language version of the GO-QOL shows evidence of validity in Graves orbitopathy and it usefully complements ophthalmic assessment in these patients.

Citing Articles

A randomised, double-masked, placebo-controlled trial evaluating the efficacy and safety of teprotumumab for active thyroid eye disease in Japanese patients.

Hiromatsu Y, Ishikawa E, Kozaki A, Takahashi Y, Tanabe M, Hayashi K Lancet Reg Health West Pac. 2025; 55:101464.

PMID: 39896230 PMC: 11787687. DOI: 10.1016/j.lanwpc.2025.101464.


Role of genetics and epigenetics in Graves' orbitopathy.

Marino M, Rotondo Dottore G, Menconi F, Comi S, Cosentino G, Rocchi R Eur Thyroid J. 2024; 13(6).

PMID: 39378053 PMC: 11623286. DOI: 10.1530/ETJ-24-0179.


Psychological aspects of Graves' ophthalmopathy.

Al-Badri W, Jellema H, Potvin A, van Nispen R, Bisschop P, Saeed P Endocr Connect. 2024; 13(9).

PMID: 39032509 PMC: 11378138. DOI: 10.1530/EC-24-0259.


Optic nerve compression associated with visual cortex functional alteration in dysthyroid optic neuropathy: A combined orbital and brain imaging study.

Zhang H, Liu Y, Jiang M, Xia D, Peng Y, Zhu L CNS Neurosci Ther. 2024; 30(7):e14820.

PMID: 38948947 PMC: 11215484. DOI: 10.1111/cns.14820.


Assessment of choroidal perfusion indices in thyroid eye disease by using optical coherence tomography.

Goel R, Shah S, Yadav U Indian J Ophthalmol. 2024; 72(11):1639-1644.

PMID: 38767537 PMC: 11668218. DOI: 10.4103/IJO.IJO_3315_23.